Louise Lutze-Mann

Director, Education Focussed Careers
Associate Professor

Research Contribution

The therapeutic use of ionising radiation for the treatment of cancer is widespread. While the benefits of such treatment are undeniable, there are concomitant and inherent risks with such treatments one of which is the possible induction of additional mutations which may lead to the initiation of new tumours. We have been analysing the effects of treatment with ionising radiation in different tissues of transgenic mice to determine the long-term effects of such treatment. There are differential rates of damage induction and removal in different tissues and while the radiological sensitivity in terms of tissue damage are known, the longer term effects in relation to persistence of damage as mutations are not. This may be particularly relevant if the irradiated cells have mutant or non-functional p53 which is a tumour suppressor gene that is mutated in over 50% of all human tumours. This work has significant implications for patient treatment regimes (the extent and duration of radiation treatment) and was funded by NASA to determine the possible health effects for astronauts on future long-haul flights such as the mission to Mars.

We have also been investigating the potential of new and existing drugs for the treatment of cancer. Our work with L-nucleoside drugs has demonstrated that they may be most effective in killing cells that have lost functional p53. This is very promising in terms of patient outcome since the majority of human tumours lack functional p53 but normal cells retain it, which means that the drugs should have a good therapeutic index and so induce less side-effects.

The other treatment regime that we have been investigating (in collaboration with scientists at the University of Queensland) is the use of anti-psychotic drugs in the treatment of cancer. It has been noted that patients with schizophrenia have a lower incidence of cancer in comparison with the overall population and this has been attributed to the drugs that these patients use to manage their disease.

We have found that these drugs preferentially kill cancer cells and, since they have the capacity to cross the blood-brain barrier, they have the potential to be used as chemotherapeutics for brain tumours, which are among the most difficult and refractory to treat. We have also found that these drugs are more cytotoxic when used in conjunction with the cholesterol lowering drugs, the statins.

This is very promising in terms of patient outcomes since it means that the level of anti-psychotic drug that will be required to achieve tumour killing is lower and hence the side-effect profile should be better. This work is the subject of a preliminary patent (Patent 06_1915-Olanzipine).

Professional Experience

  • 2016-current: Associate Professor, Deputy Head of School and Director of Teaching, School of BABS
  • 2013-2016: Senior Lecturer, Deputy Head of School and Director of Teaching, School of BABS
  • 2001-2013: Senior Lecturer, School of BABS
  • 2011 (concurrent): UNSW Faculty of Science Academic Coordinator of Learning and Teaching;
    Chair UNSW Academic Coordinators of Learning and Teaching (4 months)
  • 2002-2003: Associate Professor, California State University Channel Islands, Camarillo, CA, USA
  • 2001: Senior Lecturer, School of Biochemistry and Molecular Genetics, UNSW
  • 1997-2000: Lecturer, School of Biochemistry and Molecular Genetics, UNSW
  • 1992-1997: Assistant Research Professor, Laboratory of Radiobiology and Environmental Health, University of California, San Francisco, CA, USA

Honours & Awards

  • Australian Society for Biochemistry and Molecular Biology Education Award, 2013
    Vice-Chancellor's Award for Teaching Excellence, 2011
  • Australian Learning and Teaching Council Citation for Outstanding Contributions to Student Learning, 2010
  • UNSW Faculty of Science Award for Teaching Excellence, 2009
  • Senate Chair (elected position), California State University, Channel Islands CA, 2002-03
  • UNSW Faculty of Life Sciences Teaching Award, 2000
  • Radiation Research Society Travel Award, 1995
  • Commonwealth of Australia, Postgraduate Research Award, 1977-1981
Journal articles
add
Azad AKM; Dinarvand M; Nematollahi A; Swift J; Lutze-Mann L; Vafaee F, 2020, 'A comprehensive integrated drug similarity resource for in-silico drug repositioning and beyond.', Brief Bioinform, http://dx.doi.org/10.1093/bib/bbaa126
2020
Glenn WK; Ngan CC; Amos TG; Edwards RJ; Swift J; Lutze-Mann L; Shang F; Whitaker NJ; Lawson JS, 2017, 'High risk human papilloma viruses (HPVs) are present in benign prostate tissues before development of HPV associated prostate cancer', INFECTIOUS AGENTS AND CANCER, vol. 12, http://dx.doi.org/10.1186/s13027-017-0157-2
2017
Caruana BT; Skoric A; Brown AJ; Lutze-Mann LH, 2017, 'Site-1 protease, a novel metabolic target for glioblastoma', Biochemical and Biophysical Research Communications, vol. 490, pp. 760 - 766, http://dx.doi.org/10.1016/j.bbrc.2017.06.114
2017
Lawson JS; Glenn WK; Salyakina D; Delprado W; Clay R; Antonsson A; Heng B; Miyauchi S; Tran DD; Ngan CC; Lutze-Mann L; Whitaker NJ, 2015, 'Human Papilloma Viruses and Breast Cancer.', Front Oncol, vol. 5, pp. 277, http://dx.doi.org/10.3389/fonc.2015.00277
2015
Murray V; Taylor CB; Gero AM; Lutze-Mann LH, 2015, 'The influence of p53 status on the cytotoxicity of fluorinated pyrimidine L-nucleosides', Chemico-Biological Interactions, vol. 240, pp. 102 - 109, http://dx.doi.org/10.1016/j.cbi.2015.08.010
2015
Lutze-Mann L; Kumar RK, 2013, 'The formative assessment lecture: Enhancing student engagement', Medical Education, vol. 47, pp. 526 - 527, http://dx.doi.org/10.1111/medu.12162
2013
Lutze-Mann LH; Wijenayake N; Hovey E; Catts VS, 2012, 'PSYCHOTROPIC DRUG REPOSITIONING FOR THE TREATMENT OF GLIOBLASTOMA', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, vol. 8, pp. 64 - 65, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000306960100059&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
2012
Wiklund ED; Catts VS; Catts SV; Ng TF; Whitaker NJ; Brown AJ; Lutze-Mann L, 2010, 'Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target.', International Journal of Cancer, vol. 126, pp. 28 - 40, http://dx.doi.org/10.1002/ijc.24813
2010
Lawson JS; Glenn WK; Salmons B; Ye Y; Heng B; Moody P; Johal H; Rawlinson WD; Delprado W; Lutze-Mann L; Whitaker NJ, 2010, 'Mouse mammary tumor virus-like sequences in human breast cancer', Cancer research, vol. 70, pp. 3576 - 3585, http://dx.doi.org/10.1158/0008-5472.CAN-09-4160
2010
Kristiana I; Sharpe LJ; Catts VS; Lutze-mann LH; Brown AJ, 2010, 'Antipsychotic drugs upregulate lipogenic gene expression by disrupting intracellular trafficking of lipoprotein-derived cholesterol.', Journal of Pharmacogenomics, vol. 10, pp. 396 - 407, http://dx.doi.org/10.1038/tpj.2009.62
2010
Ross P; Ross P; Tzioumis ; Hughes C; Kofod MG; Lutze-Mann L; Whitaker NJ, 2010, 'Threshold Concepts in Learning Biology and Evolution', Biology International, vol. 47, pp. 47 - 54, http://www.iubs.org/pdf/publi/BI/Vol%2047.pdf
2010
Heng B; Glenn W; Ye Y; Tran B; Delprado W; Lutze-Mann L; Whitaker NJ; Lawson JS, 2009, 'Human papilloma virus is associated with breast cancer', British Journal of Cancer, vol. 101, pp. 1345 - 1350, http://dx.doi.org/10.1038/sj.bjc.6605282
2009
Lawson JS; Glenn W; Heng B; Ye Y; Tran B; Lutze-Mann L; Whitaker NJ, 2009, 'Koilocytes indicate a role for human papilloma virus in breast cancer', British Journal of Cancer, vol. 101, pp. 1351 - 1356, http://dx.doi.org/10.1038/sj.bjc.6605328
2009
Allen BJ; So TP; Abbas Rizvi S; Song YE; Fernandez H; Lutze-Mann L, 2009, 'Mutagenesis induced by targeted alpha therapy using 213Bi-cDTPA- 9.2.27 in lacZ transgenic mice', Cancer Biology and Therapy, vol. 8, pp. 777 - 781, http://dx.doi.org/10.4161/cbt.8.9.8110
2009
Fernandez H; Batten ML; Kugathasan K; Lutze-Mann L, 2008, 'Long-term mutagenic effects of ionising radiation on mice which vary in their p53 status', DNA Repair, vol. 7, pp. 641 - 647, http://dx.doi.org/10.1016/j.dnarep.2008.01.004
2008
Catts VS; Catts SV; Mcgrath J; Feron F; Mclean D; Coulson E; Lutze-Mann L, 2006, 'Apoptosis and schizophrenia: A pilot study based on dermal fibroblast cell lines', Schizophrenia Research, vol. 84, pp. 20 - 28, http://dx.doi.org/10.1016/j.schres.2006.03.016
2006
Kan CY; Iacopetta BJ; Lawson JS; Whitaker NJ, 2006, 'Human papilloma virus and breast cancer - Reply', British Journal of Cancer, vol. 94, pp. 339 - 339, http://dx.doi.org/10.3389/fonc.2015.00277
2006
Bachmann PS; Gorman R; MacKenzie KL; Lutze-Mann L; Lock RB, 2005, 'Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor', Blood, vol. 105, pp. 2519 - 2526, http://dx.doi.org/10.1182/blood-2004-05-2023
2005
Catts VS; Catts S; Fernandez H; Taylor J; Coulson E; Lutze-Mann L, 2005, 'A microarray study of post-mortem mRNA degradation in mouse brain tissue', Molecular Brain Research, vol. 138, pp. 164 - 177, http://dx.doi.org/10.1016/j.molbrainres.2005.04.017
2005
Tucker J; Marples B; Ramsey M; Lutze-Mann L, 2004, 'Persistence of chromosome aberrations in mice acutely exposed toFe-56(+26) ions', Radiation Research, vol. 161, pp. 648 - 655, http://dx.doi.org/10.1667/RR3177
2004
Catts VS; Haber M; Norris MD; Lutze-Mann L; Lock RB, 2001, 'High Level resistance to Glucocorticoids, assosiated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance', Leukemia, vol. 15, pp. 929 - 935, http://dx.doi.org/10.1038/sj.leu.2402128
2001
Chang PY; Kanazawa N; Lutze-Mann L; Winegar RA, 2001, 'P53 deficiency alters the yield and spectrum of radiation-induced lacZ mutants in the brain of transgenic mice', Mutagenesis, vol. 16, pp. 7 - 15, http://dx.doi.org/10.1093/mutage/16.1.7
2001
Chang PY; Kanazawa N; Lutze-Mann L; Winegar R, 2001, 'HZE particle radiation induces tissue-specific and p53-dependent mutagenesis in transgenic animals', Physica Medica, vol. 17, pp. 189 - 191
2001
Chang PY; Torous D; Lutze-Mann L; Winegar R, 2000, 'Impact of p53 status on heavy-ion radiation-induced micronuclei in circulating erythrocytes', Mutation Research - Genetic Toxicology and Environmental Mutagenesis, vol. 466, pp. 87 - 96, http://dx.doi.org/10.1016/S1383-5718(00)00007-3
2000
Xue ML; Thakur A; Lutze-Mann L; Willcox MD, 2000, 'Pro-inflammatory cytokine/chemokine gene expression in human corneal epithelial cells colonized by Pseudomonas aeruginosa', Clinical and Experimental Ophthalmology, vol. 28, pp. 197 - 200, http://dx.doi.org/10.1046/j.1442-9071.2000.00286.x
2000
Wiencke JK; Yager JW; Varkonyi A; Hultner M; Lutze LH, 1997, 'Study of arsenic mutagenesis using the plasmid shuttle vector pZ189 propagated in DNA repair proficient human cells', Mutation Research - Reviews in Mutation Research, vol. 386, pp. 335 - 344, http://dx.doi.org/10.1016/S1383-5742(97)00016-1
1997
Norris MD; Haber M; Kavallaris M; Brian MJ; Lutze LH; White L; Stewart BW, 1991, 'Reduced drug accumulation as the mechanism of extreme clinical resistance to methotrexate in the human T‐cell leukemia xenograft, LALW‐2', Cancer, vol. 68, pp. 981 - 987, http://dx.doi.org/10.1002/1097-0142(19910901)68:5<981::AID-CNCR2820680512>3.0.CO;2-W
1991
Narendranathan R; Lutze LH; Jackson GDF; Cooper GN, 1988, 'Antigens involved in resistance to mucosal association by Vibrio cholerae', Journal of Medical Microbiology, vol. 25, pp. 129 - 138, http://dx.doi.org/10.1099/00222615-25-2-129
1988
Cleaver JE; Cortés F; Lutze LH; Morgan WF; Player AN; Mitchell DL, 1987, 'Unique DNA repair properties of a xeroderma pigmentosum revertant.', Molecular and cellular biology, vol. 7, pp. 3353 - 3357, http://dx.doi.org/10.1128/MCB.7.9.3353
1987
LUTZE LH; EDWARDS MR, 1980, 'ACTIVATION AND INACTIVATION OF ACYL-COA THIOESTERASE', PROCEEDINGS OF THE AUSTRALIAN BIOCHEMICAL SOCIETY, vol. 13, pp. 24 - 24, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1980KD61300075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
1980
Conference Papers
add
Allen B; Crosky AG; Yench E; Lutze-Mann L; Blennerhassett PJ; Lebard R; Thordarson P; Wilk KE, 2010, 'A model for transformation: A transdisciplinary approach to disseminating good practice in blended learning in a science faculty', in Curriculum, technology & transformation for an unknown future. Proceedings Ascilite Sydney 2010, Queensland University Press, St Lucia, Queensland, pp. 36 - 48, presented at Ascilite 2010, Sydney, 05 December 2010 - 08 December 2010, http://www.ascilite.org.au/conferences/sydney10/procs/Allen-full.pdf
2010
Catts VS; Wiklund ED; Catts SV; Lutze-Mann LH, 2007, 'No in vitro anti-cancer effect of antipsychotic drugs at doses used in the psychiatric clinic', in SCHIZOPHRENIA BULLETIN, OXFORD UNIV PRESS, Savannah, GA, pp. 230 - 230, presented at 10th International Congress on Schizophrenia Research, Savannah, GA, 02 April 2005 - 06 April 2005, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000244506600081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
2007
Catts VS; Catts SV; Fernandez HR; Lutze-Mann LH, 2003, 'CDNA microarray assessment of MRNA degradation in postmortem brain tissue', in SCHIZOPHRENIA RESEARCH, ELSEVIER SCIENCE BV, COLORADO SPINGS, COLORADO, pp. 60 - 61, presented at 9th International Congress on Schizophrenia Research, COLORADO SPINGS, COLORADO, 29 March 2003 - 02 April 2003, http://dx.doi.org/10.1016/S0920-9964(03)80565-0
2003
Xue ML; Thakur A; Lutze-Mann L; Willcox MD, 1999, 'Pro-inflammatory cytokine/chemokine gene expression of human corneal epithelial cells colonized by Pseudomonas aeruginosa', in Australian and New Zealand Journal of Ophthalmology, Blackwell Science Asia, South Carlton, Australia, presented at Australasian Ophthalmic and Visual Sciences Meeting 1999, ANU, Canberra
1999

Cancer induction and genomc instability

Tertiary education, assessment, academic development